There is news that Glaxo Smithkline Beecham Pharmaceuticals is transferring its Rs 750 m brand, Iodex, to Smithkline Beecham Consumer Healthcare Limited (SBCH). Iodex, the leader in pain balms, is predominantly an over the counter (OTC) product, with more than 90% of sales from this route. The rest is sold through chemist shops. However, the consideration or the royalty on sales to be paid to Glaxo SmithKline is yet to be decided.
SBCH shareholders must heave a small sigh of relief. Their stock has been trading on the lower side of the FMCG valuations (P/E of 15.7x 1QFY02 annualised earnings) for quite some time. This despite the company clocking double-digit growth rates both in topline and bottomline even in this difficult environment for FMCG products. In FY01, SBCH’s topline and bottomline grew by 20.4% and 14.6% respectively. A 28% decline in the company’s other income coupled with a huge 74% jump in its interest burden was largely responsible for the sluggish growth in the bottomline.
This was because SBCH strengthened its dominating position in the malted beverages segment with the acquisition of Viva and Maltova brands from Jagatjit Industries. The company embarked on a capex plan of Rs 2.4 bn for a new plant (26,000 tonnes per annum) to manufacture 'Horlicks' (its main brand). This was done to overcome a potential capacity constraint in the future. SBCH is also increasing capacity at its existing plant by 6,000 tonnes per annum. Productivity levels are expected to improve substantially as the new plant is based on the latest available technology. As a result of this the profit growth of the company has stagnated, as it will not be able to capitalise the expenditure.
In the first quarter of FY02 SBCH declared a 26% jump in its bottomline YoY. Its topline too has grown by nearly 25% YoY. But even this has not helped the company get a re-rating because of the concerns about the future of SBCH post merger with Glaxo. There were also concerns regarding SmithKline’s other subsidiaries in India.
But if the Iodex transfer goes through then the stock might regain some of the lost confidence on the bourses. The transfer does make sense considering SBCH’s strong distribution focus. It will not only add Rs 750 m to its topline (around 10% of SBCH’s FY01 net sales) but the royalty amount is also not expected to be very high. For Horlicks, SBCH pays around 4% of the brand’s turnover as royalty to its parent.
At the current price of Rs 395 SBCH’s current market cap to net sales is around 2.4 times. Post transfer of Iodex, this market cap to net sales will stand reduced to 2.2 times.
GSK Consumer Healthcare declared results for the quarter ended September 2016. The revenues dropped by 1.3% during the quarter as compared to a year ago; while the profits declined by 16.6% YoY during the quarter.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407